Clinical Trials Logo

Cardiomyopathy Due to Drug clinical trials

View clinical trials related to Cardiomyopathy Due to Drug.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06331806 Recruiting - Clinical trials for Cardiomyopathy Due to Drug

Myocardial Fibrosis Identification in Patients With Anthracycline-induced Cardiotoxicity

Start date: February 22, 2018
Phase: N/A
Study type: Interventional

This is an interventional study for patients who had developed Anthracycline-Induced Cardiotoxicity (AIC) during or after anthracycline-containing therapy, referred to the Cardioncology Unit for heart failure treatment

NCT ID: NCT06309862 Recruiting - Clinical trials for Cardiomyopathy Due to Drug

Immune Checkpoint Inhibitor Therapy for Cancer and Risk of Myocarditis or Cardiomyopathy

Start date: June 1, 2024
Phase:
Study type: Observational

Patients undergoing dual treatment with Immune checkpoint inhibitors (ICI) for various cancers, e.g. melanoma, are at increased risk of developing myocarditis and cardiomyopathy. Currently, only limited data on serial myocardial tissue changes during treatment and whether they predict outcomes are available. Cardiac MRI (CMR) is the reference standard for non-invasive myocardial volumes/function analysis and uniquely characterizes myocardial tissue. Therefore, it may help detect myocardial tissue changes during treatment and help early treatment and prevent adverse cardiac outcomes.

NCT ID: NCT04547465 Recruiting - Breast Cancer Clinical Trials

2D Speckle-tracking Echocardiography in Chemotherapy-induced Cardiomyopathy With Cardiovascular Risk Factors

Start date: September 15, 2020
Phase:
Study type: Observational

The aims of this study is to evaluate the role of 2D speckle-tracking echocardiography in diagnosis chemotherapy related left ventricular dysfunction in breast cancer patients with cardiovascular risks